Paclitaxel CAS NO.: 33069-62-4
Active Pharmaceutical Ingredients 2025-03-03
CAS NO.: 33069-62-4
Molecular formula: C47H51NO14
Molecular weight: 853.92
Standard: USP35
Content: ≥99%
Packaging: 5kg/tin
Paclitaxel: A Comprehensive Introduction
Paclitaxel, a well – known chemotherapeutic agent, has significantly impacted cancer treatment.
1. General Information
| Aspect | Details |
| Synonym | Taxol |
| Source | Originally isolated from the bark of the Pacific yew tree (Taxus brevifolia) |
| Chemical Class | Taxane |
2. Mechanism of Action
| Action | Explanation |
| Microtubule Interaction | Binds to β – tubulin, promoting microtubule assembly and inhibiting disassembly. This leads to the formation of stable, non – functional microtubule bundles. |
| Cell Cycle Arrest | Causes cell cycle arrest in the G2/M phase, halting cancer cell division. |
| Apoptosis Induction | Prolonged cell cycle arrest triggers apoptosis, killing cancer cells. |
3. Clinical Applications
| Cancer Type | Treatment Role |
| Breast Cancer | Standard treatment, used in early – stage and metastatic cases, often in combination with other drugs. |
| Ovarian Cancer | Key drug in ovarian cancer treatment, improving patient survival. |
| Lung Cancer | Effective in non – small cell lung cancer, used as monotherapy or in combination. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
